GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » Debt-to-EBITDA

Moberg Pharma AB (OSTO:MOB) Debt-to-EBITDA : -0.16 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Moberg Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr1.29 Mil. Moberg Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr3.14 Mil. Moberg Pharma AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr-28.49 Mil. Moberg Pharma AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Moberg Pharma AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:MOB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.85   Med: 0.07   Max: 300.23
Current: -0.18

During the past 13 years, the highest Debt-to-EBITDA Ratio of Moberg Pharma AB was 300.23. The lowest was -3.85. And the median was 0.07.

OSTO:MOB's Debt-to-EBITDA is ranked worse than
100% of 661 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs OSTO:MOB: -0.18

Moberg Pharma AB Debt-to-EBITDA Historical Data

The historical data trend for Moberg Pharma AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Debt-to-EBITDA Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 300.23 - -0.23 -0.36 -0.21

Moberg Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.27 -0.15 -0.17 -0.16

Competitive Comparison of Moberg Pharma AB's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Debt-to-EBITDA falls into.



Moberg Pharma AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Moberg Pharma AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.27 + 3.467) / -23.061
=-0.21

Moberg Pharma AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.286 + 3.139) / -28.488
=-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Moberg Pharma AB  (OSTO:MOB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Moberg Pharma AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB (OSTO:MOB) Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.